Emmanuelle Clappier

This study uses patient-derived xenografts to identify TP53-associated relapse mechanisms in T-ALL, showing relapse phenotypes linked to OXPHOS metabolism and MYC signaling.

This study identifies CD20 as an actionable target in B-ALL MRD using PDX models and single-cell RNA sequencing, showing anti-CD20 antibodies can eradicate drug-resistant cells.

The paper presents a comprehensive dataset of TLX1 positive ALL-SIL lymphoblasts and primary T-ALL leukemias using polyA[+] and total RNA sequencing, ATAC sequencing, and ChIP sequencing, validated for quality and biological relevance.